Certain immunopotentiators, derived from a variety of sources, have not only an antitumour effect (Mastrangelo et al., 1981) , but also induce interferon (IFN) production in vivo (Matsubara et al., 1980) . Some immunopotentiators, as well as IFN, have been reported to augment natural killer (NK) cell activity, stimulate macrophages (MO) to become tumouricidal, generate cytotoxic T lymphocytes (CTL), and enhance various nonspecific immune responses both in vivo and in vitro (Mastrangelo et al., 1981; Vilcek et al., 1980) . Carboxyethylgermanium sesquioxide [03(GeCH2CH2COOH)2], an organogermanium compound originally synthesized at Asai Germanium Research Institute, Tokyo, Japan (Tsutsui et al., 1976) , is an immunopotentiating agent (Arimori et al., 1981b; Mizushima et al., 1980; Suzuki et al., 1984) with IFN-inducing (Aso et al., 1985; Miyao et al., 1980) and antitumour activities (Kumano et al., 1980; Arimori et al., 1981a; Satoh & Iwaguchi, 1979) .
Acute and chronic toxicities of the compound were determined in Wistar rats (acute and chronic) or beagle dogs (chronic) by i.v. (125-500mgkg-1) or oral (30-3,000mgkg-1) administration. At all doses examined, no significant toxicity was detected (Miyao et al., 1980; Nagata et al., 1978) . The physiocochemical characteristics and pharmacokinetics of the compound have been described previously (Miyao et al., 1980; Tomisawa et al., 1978) . As an immunotherapeutic agent for cancer, this compound has undergone some clinical testing in Japan.
The antitumour activity of Ge-132 in ascites tumour-bearing mice was eliminated by the in vivo administration of monoclonal anti-Thy 1.2 antibody (anti-Thyl.2 mAb), which has been reported to cause a disappearance of Thy-1.2+ cells from mice (Nakayama & Uenaka, 1985; Opitz et al., 1982) , or macrophage (MO) blockers, such as trypan blue and carrageenan (Chaout & Howard, 1976; Hibbs, 1975) . However, the antitumour effect of Ge-132 was not blocked by in vivo treatment with anti-asialo GM1 antiserum which has been reported to eliminate NK cell activity (Habu et al., 1981) . This suggested that the protective effect displayed by Ge-132 was expressed through the function of T lymphocytes and/or MO (Suzuki, 1985a, b) .
The elimination of T-cells by anti-Thy 1.2 antibody and complement has been shown to result in the suppression of interleukin 2 (IL-2) (Muhlradt & Opitz, 1982) and IFN gamma (IFN y) production (Sonnenfeld et al., 1979) , as well as the generation of CTL (Wong et al., 1977) . It has also been reported that IL-2 production, CTL generation, and the augmentation of NK cell activity may be influenced by IFNy (Kasahara et al., 1983; Torres et al., 1982; Weigent et al., 1983) . The oral administration of Ge-132 was reported to stimulate the production of IFN y in the sera of mice (Aso et al., 1985) , and this type of IFN appears to be produced by T lymphocytes (Chang et al., 1982; Sonnenfeld et al., 1979) . Therefore, in the present paper, we investigated the role of IFN y, one of the lymphokines (Epstein, 1981) induced by in the sera of mice, on the antitumour properties of the compound.
Materials and methods

Mice and tumours
Eight-week-old male and female inbred BALB/c and C57BI/6 mice were used (Suzuki, 1985a,b) . Ehrlich (allogeneic), and RL31 (syngeneic) ascites tumours were serially passaged in BALB/c mice by i.p. injection of 1 x 106 cells per mouse (Suzuki, 1985a,b) .
IFN assay and IFN standard
Mouse IFN activity was assayed by a microplaque reduction method (Suzuki & Pollard, 1982 (Osborne et al., 1980a,b) .
Preparation of sera
The C57B1/6 mice received a 100mg kg1 body wt oral dose of Ge-1 32 or a 0.5 ml per mouse oral dose of saline as a control. Twelve to 48 h later the mice were sacrificed and blood samples were maintained at 4°C overnight, centrifuged at 1,250g for 30 min, and the supernatants (serum specimens) were stored at -70°C.
Inactivation of IFN activity
Twenty ml of serum IFN (360 U ml 1) obtained from mice 24 h after Ge-132 administration or murine IFN y (400 U ml-) were mixed with an equal volume of anti-IFN y (400 IFN neutralizing U ml-1) or normal rabbit serum (control) and kept at room temperature for h (Osborne et al., 1980a, b) . Then, 0.5 ml was injected i.p. to tumourbearing mice. The inactivation of the serum IFN induced by Ge-132 and murine IFN y by trypsin or acid pH treatment was performed as previously described (Aso et al., 1985) . Briefly, both IFN y preparations were treated with 200 igml-l of trypsin at 37°C for 2h or dialyzed against 0.1M glycine-HCl buffer (pH2.0) at 4°C for 12h, and then redialyzed against 0.1M PBS (pH 7.0). After inactivation, these preparations were stored at -700C.
Antitumour assay of serum specimens in vivo One day before Ehrlich or RLd1 tumour cell inoculation (1 x 105 cells per mouse, i.p.), BALB/c mice received an i.p. injection of 0.5ml of either a 1: 5 dilution of serum obtained from mice at various intervals after oral Ge-132 (100mg kg-1 body wt) administration, the same dilution of control serum obtained from mice 24h after oral saline (0.5ml per mouse) injection, a 5,000 U kg-1 body wt i.p. dose of murine IFNy, or a 100mgkg-1 body wt oral dose of Ge-132. In some experiments, tumourbearing mice received an i.p. injection of serum IFN inactivated by trypsin or acid pH treatments, or with antiserum-inactivated IFN y. These treatments of tumour-bearing mice were performed once every other day for a total of 10 injections. Mice were observed daily in order to determine the mean survival days (MSD). Each experiment was terminated 50 days after tumour inoculation, and the percent survival was calculated from the number of mice surviving more than 50 days. The influence of these preparations on tumour growth was evaluated by MSD and survival percent as compared with controls (Suzuki, 1985a ).
Statistical analysis
As described previously (Suzuki, 1985a, b) , statistical significance was determined by Student's t-test or x2 analysis. The results were considered significant if P<0.05.
Results
Antitumour activity of sera To determine the antitumour activity of sera obtained 24 h after Ge-132 administration, 20 BALB/c mice bearing Ehrlich tumours were treated i.p. with 0.5 ml of a 1:5 dilution of the serum from Ge-132-treated mice (Ge-mice) or normal control mice. As a positive control, one group of 30 mice was treated with a 100mg kg-I body wt oral dose of Ge-132, and a group of 40 mice was injected orally with 0.5 ml per mouse of saline as a tumour control. As shown in Table IA , Ge-132 and serum from Ge-mice significantly increased the MSD of tumour-bearing mice compared to those of tumour controls conferring 37 and 40% survival, respectively. In order to determine if sera from Ge-mice were also effective against a syngeneic ascites tumour (RL&1) in vivo, tumour-bearing mice were treated in the same fashion as in the Ehrlich experiments. As shown Table IB, sera from Ge-mice also inhibited the growth of RLdl ascites tumours in BALB/c mice (40% survival, P=0.025) as did administration (45% survival, P<0.001), while all control mice treated with saline or normal mouse serum died within 34 days after tumour inoculation. Thus, sera from Ge-mice were as active in vivo against Ehrlich and RLS1 ascites tumours as Ge-132 administration. Dose response effect of sera Various dilutions of sera obtained 24 h after administration of Ge-132 were injected into mice bearing Ehrlich tumours. Eight groups of tumourbearing mice (20 mice each) received i.p. injections of 0.5ml of a 1:1 (0.5ml), 1:4 (0.12ml), 1:16 (0.03 ml), or 1:64 (0.007 ml) dilution of serum obtained from Ge-mice or normal mice. As illustrated in Figure 1 , significant antitumour activity of sera from Ge-mice was noted at dosages of 0.5ml per mouse (70% survival, P<0.001) and 0.12 ml per mouse (40% survival, P= 0.002), while <0.03 ml per mouse and all concentrations of normal mouse serum had no effect. These results indicate that the antitumour properties of sera from Ge-mice was dose dependent. Correlation between antitumour activity of sera and appearance of IFN To determine if there was a correlation between the appearance of IFN and the antitumour activity induced by Ge-132, sera were harvested after an oral dose of Ge-132 (100mgkg-1 body wt) every 6 h for 48 h. As shown in Figure 2 , IFN appeared 18 h after Ge-1 32 administration with maximum levels (360Uml-1) detected at 24h and gradually decreased thereafter until 42h when no IFN was observed. Sera obtained from mice 12, 24, 36 and 48 h after Ge-132 administration, and labelled A, B, C, and D, respectively, were tested for their antitumour activity in Ehrlich-bearing mice. Five groups (20 mice each) were treated i.p. with 0.5ml of a 1:5 dilution of specimens A to D or 0.5 ml per mouse of saline, and observed for survival. As shown in Figure 2 , specimens A, C, and D had no antitumour activity, while samples B and C produced 40% (P<0.001) and 10% survival, respectively. Therefore, the maximum antitumour activity correlated with the highest IFN titre which was noted 24h after Ge-132 administration. Figure 4 . Failure of protection of tumour-bearing mice by two IFN preparations treated with anti-IFN y antiserum. 20 ml of serum IFN (360 U ml-of IFN activity) obtained from Ge-mice and murine IFN y (400 U ml-1 of IFN activity) were treated with the same amount of anti-mouse IFN y antiserum (400 IFN neutralizing U ml-1), and 0.5 ml of these preparations was injected to mice bearing 1 x IO' Ehrlich cells (neutralized serum IFN, *; neutralized murine IFN y, *). As positive or negative controls, tumour-bearing mice were given i.p. 0.5 ml of serum IFN (4,500 IFN U kg-I body wt, A), murine IFN y (5,000 IFN U kgbody wt, C]), and saline (0).
(control for dialysis) protected 50% (P<0.001) and 40% (P <0.001) of the mice, respectively, serum exposed to pH 2.0 or trypsin treatment did not influence survival. In addition, when IFNcontaining samples were treated with anti-IFN y, no antitumour effect was noted in a group of 10 tumour-bearing mice (Figure 4) . Increased survival was observed in mice treated with murine IFN y (5,000 U kg-body wt, 20 mice, 40% survival, P<0.001), or IFN-containing serum from Ge-mice (4,500 U kg-' body wt, 40% survival, 20 mice, P <0.001). The tumour controls (30 mice) died within 23 days of inoculation.
Discussion
The antitumour activity of sera obtained from Gemice against syngeneic (RL31) or allogeneic (Ehrlich) ascites tumours in mice appeared similar to that observed with the compound itself. In addition, the serum-mediated antitumour effect correlated with IFN levels present and this association was confirmed by kinetic and inactivation studies. The maximum antitumour activity in the serum was observed at the time of the highest serum IFN titer (24h after Ge-132 administration). The inactivation of the IFN activity in sera from Ge-mice was accomplished by treatments with acid pH, trypsin or anti-IFN y and abolished antitumour activity. The serum IFN induced by Ge-132 in mice was identified as IFN y since its activity was eliminated by treatment with low pH and anti-IFN y. These results indicate that the antitumour activity of the compound in mice bearing experimental ascites tumours is reconstituted by administration of the IFN y containing sera from Ge-mice.
As compared to IFN a and I, IFN y has been demonstrated to be a more potent mediator of antitumour activities (Crane et al., 1978) . Therefore, repeated administration of mouse IFN y preparations resulted in the marked inhibition of the growth of transplantable murine tumours and increased the survival of tumour-inoculated mice (Crane et al., 1978; Salvin et al., 1975; Gresser, 1983) . On the other hand, the antitumour activity of Ge-132 appears to involve MO, since the administration of MO blockers prevented the expression of the antitumour activity of Ge-132 (Suzuki, 1985a) , the passive transfer of MO from Ge-mice conferred antitumour resistance to untreated tumour-bearing mice (Suzuki, 1985b) , and MO from Ge-Mice also had cytotoxic properties in vitro against certain tumours which were sensitive to the antitumour activity of Ge-132 in vivo (Suzuki, 1985b) . Some reports (Kleinschmidt & Schultz, 1982; Robert & Vasil, 1982) suggest that the induction of tumouricidal MO from a resting state requires IFN y which induced the priming step (Pace et al., 1982) in MO activation, or acts as a cofactor associated with M4-activating factor (Mannel & Falk, 1983) . In addition, it was also demonstrated that the in vivo administration of anti-Thyl.2 mAb, effectively prevented the expression of antitumour activity of Ge-1 32 761 (Suzuki, 1985a) . As presented here, the antitumour activity of Ge-132 appeared to be expressed through the induction of lymphokine(s), such as IFN y, and since lymphokines have been shown to be produced by T lymphocytes (Epstein, 1981) , it is possible that the activity of Ge-132 against tumours may be due to the following properties: (i) the compound exhibits antitumour activity which can be blocked by the exogenous administration of Tcell or MO blockers, (ii) MO obtained from Ge-mice display antitumour activity in vivo and in vitro, (iii) sera from Ge-mice contain IFN y, one of the lymphokines which is produced by T-cells, (iv) 
